Market Insight - Spinning off assets, AstraZeneca-style
This article was originally published in Scrip
In the right hands, big pharma's non-core products can be allowed to flourish in newly-formed independent biotech companies. Pete Chan charts one year in the life of AstraZeneca spin-out Albireo.
Every pharmaceutical company under the sun will tell you that it has great scientific assets. But what happens when some of those compounds are deprioritised by a management team's strategic review?